Chronic migraine in women.

Abstract

Chronic migraine is a frequent, severely disabling headache that often evolves from EM. Treatment should be individualized with consideration of the patient as a whole person rather than just the headaches. Many options have been used for acute and preventive pharmacologic management, although good scientific and clinical evidence is limited to a few options. Evidence supports the efficacy and tolerability of both topiramate and onabotulinumtoxinA for prevention of CM headaches. However, only onabotulinumtoxinA is approved by the FDA for preventive treatment of CM.

• Authors: Roger K Cady
• Journal: The Journal of family practice (J Fam Pract) Vol. 63 Issue 2 Suppl Pg. S46-51 (Feb 2014) ISSN: 1533-7294 [Electronic] United States
• PMID: 24527485 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Neuroprotective Agents
• Serotonin 5-HT1 Receptor Agonists
• Topiramate
• Fructose
• Sumatriptan
• Botulinum Toxins, Type A

Topics

• Adult
• Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)
• Botulinum Toxins, Type A (therapeutic use)
• Female
• Fructose (analogs & derivatives, therapeutic use)
• Humans
• Migraine Disorders (diagnosis, etiology, therapy)
• Neuroprotective Agents (therapeutic use)
• Serotonin 5-HT1 Receptor Agonists (therapeutic use)
• Sumatriptan (therapeutic use)
• Topiramate